Colon cancer screening is only effective if you complete the test. With 53,000 Americans expected to die from colon cancer in ...

Mainz Biomed has announced a partnership with Quest Diagnostics to support the commercialisation of its NextGen colorectal ...

Quest to Support Mainz Biomed’s ReconAAsense FDA Study and Has Option to Commercialize Test Kit Assuming FDA ApprovalBERKELEY ...

(RTTNews) - Mainz Biomed N.V. (MYNZ), Thursday announced a collaboration with Quest Diagnostics Inc. (DGX) to commercialize the former's NextGen screening test for colorectal cancer, called ColoAlert ...

Cases of colorectal cancer have been rapidly increasing among young adults, so we spoke to a doctor to get some helpful tips.

to support commercialization of Mainz Biomed’s NextGen screening test for colorectal cancer. Mainz Biomed’s stool-based ColoAlert test is designed to detect colorectal cancer tumor DNA to aid ...